A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Conditions
Solid Tumors
Conditions: Keywords
Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Pancreatic Neoplasms
Study Type
Interventional
Study Phase
Phase 1
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: DS6051b
Type: Drug
Overall Status
Recruiting
Summary
DS-6051b is an orally administered inhibitor of the tyrosine kinases ROS1 and NTRKs. This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.
Detailed Description
The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.

After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available

2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:

- Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

- Neuroendocrine tumors

- Solid tumors with tumor-induced pain

3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:

- NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

- k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement

- Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

- Pulmonary LCNEC;

4. Male or female ≥18 years of age

5. Eastern Cooperative Oncology Group performance status 0 to 1

6. Adequate organ function

7. Adequate blood clotting function

8. Women of childbearing potential must have a negative pregnancy test

9. Willingness to provide archival tumor samples

10. Other inclusion criteria may apply

Exclusion Criteria:

1. Hematological malignancies

2. Known positive HIV infection, or active hepatitis B or C infection

3. Comorbidity that would interfere with therapy

4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant

5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor

6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4

7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement

8. Unresolved toxicities from previous anticancer therapy

9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment

10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment

11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment

12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein

13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption

14. QTcF values higher than 450 ms at screening

15. Breastfeeding

16. Other exclusion criteria may apply
Location
Translational Genomics Research Institute (TGen)
Scottsdale, Arizona, United States
Status: Recruiting
Contact: Daniel Von Hoff, MD
Start Date
September 2014
Completion Date
December 2017
Sponsors
Daiichi Sankyo Inc.
Source
Daiichi Sankyo Inc.
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page